The ICH E14 guidance on how to clinically assess a new drug's liability to prolong the QT
interval was adopted in May 2005. A centre‐piece of the guidance was the establishment of …

… Therefore, the different correction methods gave conflicting results of drug effect (Figure 1B).
QTcI fixed inaccurately excluded a significant effect because the uppers of 2-sided 90% CIs …

A collaboration between the Consortium for Innovation and Quality in Pharmaceutical
Development and the Cardiac Safety Research Consortium has been formed to design a clinical …

Twelve patients with severe obstructive sleep apnoea were included in an open, long-term,
prospective, follow-up study addressing the effects of nasal continuous positive airway …

The incidence of drug-induced proarrhythmias in the general population is largely unknown.
Knowledge regarding incidence and risk factors is mainly derived from studies during …

The QT effects of five “QT‐positive” and one negative drug were tested to evaluate whether
exposure–response analysis can detect QT effects in a small study with healthy subjects. …

… and/or confusional states, with clinically significant laboratory or ECG abnormalities,
haematological, hepatic, cardiac, or renal diseases or a history of infections with HIV or hepatitis B …

… B, exposure after multiple doses of twice normal dose. The exposure is increased in parallel
for both moieties. C, multiple doses of normal dose, concomitantly with metabolic inhibitor, …

The aim of this study was to identify predictors of torsades de pointes (TdP) in patients with
atrial fibrillation (AF) or flutter exposed to the Class III antiarrhythmic drug almokalant. TdP …

… The left atrial diameter was unchanged, but the area decreased in group B after the ablation …
in group B than in group A (P < 0 05). In group A no change was observed, but in group B a …